Valuation: VERE THER

Market Cap 99Cr 88Cr 82Cr 75Cr 141.72Cr 9.56TCr 143.04Cr 997.68Cr 386.6Cr 4.89TCr 373.25Cr 365.15Cr 16TCr P/E 2023
-4.47x
P/E 2024 -2.4x
Enterprise Value 54Cr 48Cr 45Cr 41Cr 77Cr 5.19TCr 78Cr 541.77Cr 209.93Cr 2.65TCr 202.68Cr 198.28Cr 8.51TCr EV / Sales 2023
4,64,30,598x
EV / Sales 2024 7,17,743x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
3 years 2.86
Extreme 2.8647
20.12
5 years 2.86
Extreme 2.8647
56.18
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 25/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
25/07/25 Tender

Chief Technology Officer

5,38,331 0.6358%
25/07/25 Tender

Chief Administrative Officer

5,34,066 0.6308%
25/07/25 Tender

Founder

33,97,141 4.0125%

Financials

2023 2024
Net sales 11.76 10.45 9.75 8.89 16.76 1.13T 16.92 118 45.72 577.84 44.15 43.19 1.85T 32.33 28.73 26.81 24.44 46.09 3.11T 46.52 324.47 125.73 1.59T 121.39 118.76 5.1T
Net income -20Cr -18Cr -17Cr -15Cr -29Cr -1.92TCr -29Cr -200.78Cr -78Cr -983.22Cr -75Cr -73Cr -3.16TCr -20Cr -18Cr -16Cr -15Cr -28Cr -1.91TCr -29Cr -199.42Cr -77Cr -976.54Cr -75Cr -73Cr -3.13TCr
Net Debt -55Cr -49Cr -46Cr -41Cr -78Cr -5.28TCr -79Cr -551Cr -213.51Cr -2.7TCr -206.14Cr -201.66Cr -8.66TCr -45Cr -40Cr -38Cr -34Cr -65Cr -4.37TCr -65Cr -455.92Cr -176.67Cr -2.23TCr -170.57Cr -166.86Cr -7.17TCr
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. VERV Stock